Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

PURPOSE: Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed antitumor activity in preclinical studies of MTC. PATIE...

Full description

Saved in:
Bibliographic Details
Main Authors: Lam, Elaine T., Ringel, Matthew D., Kloos, Richard T., Prior, Thomas W., Knopp, Michael V., Liang, Jiachao, Sammet, Steffen, Hall, Nathan C., Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Snyder, Pamela J., Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Moley, Jeffrey F., Villalona-Calero, Miguel A., Shah, Manisha H.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2010
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2881718/
https://ncbi.nlm.nih.gov/pubmed/20368568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0068
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items